What is Keytruda’s target (mechanism of action)?
Keytruda (pembrolizumab) targets the immune checkpoint receptor PD-1 (programmed death-1) on T cells. By blocking PD-1, it helps restore T-cell activity against tumor cells. [1]
What does “PD-1 blockade” mean for patients?
When PD-1 is blocked, T cells are more able to recognize and attack cancer cells. That shift in immune signaling is why Keytruda can work across multiple tumor types, depending on the cancer’s biology and other treatment factors. [1]
Which tumors are Keytruda used for (based on PD-1 target biology)?
Because the target is PD-1, Keytruda is used in settings where immune checkpoint inhibition is clinically relevant, including cancers such as melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and others. The exact indication depends on the country’s label and the specific patient/tumor markers or prior therapy history. [1]
Is Keytruda the same target as Opdivo?
Yes in the key sense that both are PD-1 inhibitors. Opdivo (nivolumab) also blocks PD-1, though the drugs are different antibodies with different dosing regimens and approved indications. [2]
How does Keytruda differ from therapies targeting PD-L1?
PD-L1–directed drugs block the ligand (PD-L1) rather than PD-1 itself. Keytruda blocks PD-1, which changes the immune interaction upstream of PD-L1 binding. Both strategies aim to boost T-cell responses, but they are not the same target. [1]
What to check if you’re researching Keytruda’s target for a study or drug comparison?
If you’re comparing therapies or reading clinical materials, look for the specific mechanism line (e.g., “anti–PD-1”) and confirm whether the comparator is PD-1 (like Keytruda/Opdivo) or PD-L1 (different target). That distinction usually explains differences in trial design and eligibility criteria.
Sources
[1] https://www.drugs.com/keytruda.html
[2] https://www.drugs.com/opdivo.html